StockData

BioHarvest Sciences vs Jaguar Health

BHST and JAGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BHST and JAGX compare

Jaguar Health grew revenue faster over the last twelve months (136% versus 37.0% for BioHarvest Sciences).

BioHarvest Sciences scores higher on the StockData Score (5 against 3 for Jaguar Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBHSTJAGX
Size and price
Market cap–$2.1M
Share price$1.50$0.400
Change, 1 year−80.9%−100.0%
Change, 5 years−86.1%−100%
Beta (5Y)0.872.17
Employees–47
StockData Score
Total score5 (better)3
Valuation score01 (better)
Growth score22
Performance score1 (better)0
Health score2 (better)0
Dividend score00
Valuation
P/S–0.1×
Growth
Revenue growth (TTM)37.0%136% (better)
Revenue growth, 5Y average–4.2%
Profitability
Gross margin59.3%82.3% (better)
Operating margin−16.2% (better)−93.1%
Net margin−32.3%–
FCF margin−27.8%–
Return on equity−83.2%–
Return on invested capital−163%–
Financial health
Debt / equity0.01–
Interest coverage–−25.9×
Current ratio3.97 (better)0.69
Altman Z-score–−18.45
Piotroski F-score5 (better)2
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions7.4%–
Held by insiders0.00%17.1%
Short interest, % of float0.33%4.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.